No Data
No Data
Aopumai (688293.SH): Shareholders Huajie Investment collectively reduced their shareholding by 1.0499% in the company.
On August 7th, Gelonhui reported that Aupuma (688293.SH) announced that on August 7, 2024, it received a notice from Huajie Investment, a shareholder holding more than 5% of the company's shares, about the reduction of shareholding proportion reaching 1%. Huajie Investment reduced its holding of the company's shares by a total of 1,205,000 shares through block trading from February 29, 2024 to August 7, 2024, accounting for 1.0499% of the total share capital of the company. After this equity change, Huajie Investment holds 9,929,542 shares of the company, accounting for 8.6% of the total share capital.
An Intrinsic Calculation For Shanghai OPM Biosciences Co., Ltd. (SHSE:688293) Suggests It's 31% Undervalued
Aupomi (688293.SH) granted reserved 0.176 million restricted stocks to incentive targets.
On August 2nd, Gelonhui reported that Opumai (688293.SH) held the second meeting of the second board of directors and the third meeting of the second supervisor board on August 2, 2024. The proposal to grant reserved restricted stocks to incentive objects under the restricted stock incentive plan in 2023 was approved, and the grant date of the incentive plan was determined as August 2, 2024. 0.176 million restricted stocks will be granted to 47 eligible incentive objects at a grant price of 25.00 yuan per share.
Aopu Mai (688293.SH): currently the company has not laid off any employees.
Oupu Mai (688293.SH) recently stated during a reception with institutional investors that the company has not downsized. In the current unfavorable environment, all industries are facing the same difficulties. At the end of last year, the company launched its corporate annuity plan, hoping to enhance employee benefits, attract talent, and fulfill its social responsibilities.
The business team in the USA of Aopu Mai (688293.SH) has now been basically established.
Aopumai (688293.SH) stated during a recent meeting with institutional investors that their USA business team has mostly been established and team members have diverse backgrounds and rich experience. This year, the integration of different corporate cultures in the USA and China is more important for the USA team. Currently, they are also successfully negotiating with MINC in the USA, products have been tested in some American pharmaceutical companies, and some pharmaceutical companies will also visit the company for on-site audits and visits in the future. There will be more opportunities for cooperation in the future, but it will still take time from business contact to order fulfillment.
The controlling shareholder of Aupu Bio (688293.SH) proposed to distribute mid-term dividend for the year 2024.
Aupu Mai (688293.SH) announced that the company recently received a notice from the company's controlling shareholder, actual controller and directors ...
No Data